EVERSANA, a pioneer of next-generation commercial services to the global life sciences industry, partnered with WorldQuant Predictive (WQP), a market leader in quantitative predictions and data-driven decisions through a cloud-based artificial intelligence (AI) platform, to improve the end result for patients.
A Phase III trial of NurOwn (MSC-NTF cells), BrainStorm Cell Therapeutics’ investigational therapy for amyotrophic lateral sclerosis, did not find a statistically significant difference between the product and placebo for improving scores on a revised ALS functional rating scale (ALSFRS-R) that measures the severity of the disease.
PharmaLive talked to Conran Design Group Managing Director Christina Falzano about her experiences working with tech companies’ expansion into the health, wellness and pharma spaces in driving changes in the healthcare industry – especially in how they reposition post-COVID.
Ugur Sahin, founder and chief executive officer of Germany-based BioNTech, sees the potent efficacy of BNT162b2 – the vaccine developed by his company and partner Pfizer – as the possible “beginning of the end” of the coronavirus pandemic.
EVERSANA announces broad-scale strategic partnerships with industry leaders in claims, EMR, formulary and provider-institutional data to optimize real-time commercial services EVERSANA and Symphony Health announce multi-year relationship for EMR claims and data infrastructure EVERSANA and Compile partner to integrate physician affiliation data to drive market access commercial services, with additional formulary data partnership in final […]
Biogen Inc. showed “exceptionally persuasive” evidence that the company’s experimental Alzheimer’s disease drug aducanumab is effective, U.S. Food and Drug Administration staff said, elevating chances of a swift approval and sending company shares soaring.
U.S. health experts this week will decide whether to recommend approval for Biogen Inc.’s experimental Alzheimer’s drug, which could become the first new treatment for the mind-wasting disease in decades even as serious questions persist over whether data show if the antibody aducanumab works.
Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.
Roche and Atea Pharmaceuticals are partnering to develop, manufacture and distribute AT-527, Atea’s experimental antiviral drug against Covid-19.
A federal appeals court threw out an order requiring AbbVie Inc. and a partner to disgorge $448 million in profit for trying to keep generic versions of the blockbuster testosterone replacement drug AndroGel off the market.